Evidence map›Paper›PMID 35988104›Full record

ArticleMolecular biology reports2022

The role of FASL, BCL-2 and BAX polymorphisms in brazilian patients with prostate cancer and benign prostatic hyperplasia.

Gabriela Kniphoff da Silva Lawisch, Vanderlei Biolchi, Gabriela Kaufmann, Gabriela Nicolai, Eduarda Capitaneo, Thais Regina Rosembach, Janaina Zang, Ilma Simoni Brum, José Artur Bogo Chies

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Positive correlation betweenInternational journal of reproductive biomedicine · 2024
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Gabriela Kniphoff da Silva LawischUniversity of Vale do Taquari - Univates, Lajeado, Brazil.
Vanderlei BiolchiUniversity of Vale do Taquari - Univates, Lajeado, Brazil.
Gabriela KaufmannUniversity of Vale do Taquari - Univates, Lajeado, Brazil.
Gabriela NicolaiUniversity of Vale do Taquari - Univates, Lajeado, Brazil.
Eduarda CapitaneoUniversity of Vale do Taquari - Univates, Lajeado, Brazil.
Thais Regina RosembachUniversity of Vale do Taquari - Univates, Lajeado, Brazil.
Janaina ZangUniversity of Vale do Taquari - Univates, Lajeado, Brazil.
Ilma Simoni BrumUniversidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
José Artur Bogo ChiesUniversidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. jabchies@terra.com.br.
Univates · BRUniversidade Federal do Rio Grande do Sul · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 473115/2011-5 and 305839/2015-2Coordenação de Aperfeiçoamento de Pessoal de Nível Superior Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorFundação de Amparo à Pesquisa do Estado do Rio Grande do Sul 14/2253-2 PqG
6 · The paper itself

Abstract

backgroundProstate cancer (PCA) is one of the leading causes of death among men, being related to several factors, including the aging male population, like benign prostatic hyperplasia (BPH), a histopathological and hyperplastic alteration associated to prostate aging. The FASL, BCL-2 and BAX genes are involved in cell apoptosis regulation and can be related to the development of both cancer and hyperplasia. This study aimed to investigate the association of FASL - 844 (rs763110), BCL-2 -938 (rs2279115) and BAX - 248 (rs4645878) polymorphic variants in Southern Brazilian PCA and BPH patients and healthy controls. METHODS AND

results348 samples were analyzed, being 123 from PCA patients, 143 BPH patients and 82 healthy controls, using PCR-RFLP techniques. The results of genotyping analysis were adjusted by age, and compared with PSA levels and prostate volume. The analyzes of genotype frequencies according to PCA, HPB and controls, were performed by logistic regression corrected by age, and showed that the FASL CC genotype can be a risk factor for PCA patients, when compared to controls (p = 0.041). The clinical data investigation indicated higher PSA levels in PCA patients with FASL CC genotype, as compared to TC genotype carriers (p = 0.044), higher PSA levels for healthy individuals with BCL-2 AA genotype, comparing with CC genotype (p = 0.027) and higher PSA levels in BPH group with FASL CC genotype, as compared to TC genotype (p = 0.044).

conclusionsOur data indicate the FASLCC genotype as a risk factor for prostate pathologies, whileBCL-2 CC can act as a protective genotype.

Indexed as

Prostatic HyperplasiaProstatic Neoplasmsbcl-2-Associated X ProteinBrazilFas Ligand ProteinHumansMaleProstate-Specific AntigenProto-Oncogene Proteins c-bcl-2BAX protein, humanbcl-2-Associated X ProteinBCL2 protein, humanFASLG protein, humanFas Ligand ProteinProstate-Specific AntigenProto-Oncogene Proteins c-bcl-2ApoptosisBAXBCL-2Benign prostatic hyperplasiaFASlProstate cancer

Identifiers

PMID35988104
OpenAlexW4292522090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.